X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition will provide Clade with preclinical cell therapy programs, g/d TCR discovery engine and a suite of cell enhancement to improve anti-tumor activity of cell therapies.
Lead Product(s): TEG002
Therapeutic Area: Oncology Product Name: GDT002
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Clade Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2023
Details:
Gadeta is developing ‘201 TCR in its proprietary TEG (T Cells Engineered to Express a Defined Gamma Delta TCR) cell therapy platform as GDT201. Pre-clinical data for GDT201 show promising results across a wide range of colorectal cancer cell lines.
Lead Product(s): GDT201,Tebentafusp-tebn
Therapeutic Area: Oncology Product Name: GDT201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Immunocore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2022
Details:
GDT002 has a potent anti-tumor activity across a broad spectrum of solid and liquid tumor types as well as to discuss the data behind our decision to select ovarian cancer as an indication to explore the clinical effect of GDT002 against solid tumors.
Lead Product(s): GDT002
Therapeutic Area: Oncology Product Name: GDT002
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma.
Lead Product(s): Gamma delta T-cell receptor based immunotherapies
Therapeutic Area: Oncology Product Name: GDT-002
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
